Safety and Performance of OsStic Bone Void Filler

  • Research type

    Research Study

  • Full title

    Safety and Performance of OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler in a First-in-Human Application to Treat Tibial Fractures.

  • IRAS ID

    360651

  • Contact name

    Peter Giannoudis

  • Contact email

    peter.giannoudis@NHS.net

  • Sponsor organisation

    Biomimetic Innovations Ltd

  • ISRCTN Number

    ISRCTN94484905

  • Duration of Study in the UK

    2 years, 3 months, 30 days

  • Research summary

    This study is the first time the OsStic Synthetic Injectable Structural Bio‑Adhesive Bone Void Filler (“OsStic BVF”) will be used in patients. The study aims to find out if this new device can be used safely alongside standard surgery for tibial plateau fractures — a break at the top of the shin bone near the knee. These injuries are difficult to repair because they can create gaps in the bone (bone voids) and small, fragile pieces that are hard to hold in place with plates and screws alone.

    OsStic BVF is a man‑made (synthetic) material with no animal or human tissue. It comes as a sterile powder and liquid, which are mixed in the operating theatre and injected into the fracture. The material hardens quickly without producing heat, helping to hold bone fragments together and fill the gaps. Over time, it dissolves naturally and is replaced by the patient’s own bone as healing occurs.

    The main question this research will answer is: Can OsStic BVF be used safely in surgery to repair these fractures? The study will also look at early performance, including whether the material stays in place and supports the fracture during recovery.

    Adult patients with suitable tibial plateau fractures will be invited to take part. All participants will receive standard fracture surgery plus OsStic BVF. Recovery will be followed for up to 12 months, using X‑rays, physical function tests, and patient questionnaires.

    If the results are positive, this research could lead to larger studies and, in the future, a new treatment option to improve bone stability, reduce complications, and support better recovery after complex joint‑related fractures.

  • REC name

    West of Scotland REC 4

  • REC reference

    26/WS/0002

  • Date of REC Opinion

    27 Feb 2026

  • REC opinion

    Further Information Favourable Opinion